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To evaluate disease course in juvenile idiopathic arthritis
(JIA) by applying newly developed preliminary defini-
tions of remission, to assess probability of relapse of dis-
ease. Charts of patients with JIA followed since 1970 were
reviewed. First episode of remission off medication status,
as defined by Wallace et al., has been focused. The cohort
included 761 patients (67.8% females, 32.2% males) with
JIA. Mean disease onset age (± SD) was 6.25 ± 4.4 years
(range 0.5–15.9). Disease mean duration to last visit was
10.02 ± 4.31 years. Follow up mean period was 7.6 ± 6.4
years (range 1.5–35 years). A total of 263 (34.56%)
patients achieved remission according to criteria (persist-
ent oligoarthritis 42.9%, extended oligoarthritis 13.1%,
seronegative polyarthritis 22.4%, systemic arthritis
33.7%, enthesitis related arthritis (ERA) plus juvenile pso-
riatic arthritis (JPsA) 33.4%. No patients with seropositive
polyarthritis achieved remission status (p < 0.001). In
remitted patients the mean survival function (± SEM)
before relapse calculated by life table survival curve was of
20.9 (± 1.3) months overall: 21.7 (± 0.46) in persistent
oligoarthritis, 25.0 (± 6.6) in extended oligoarthritis, 26.7
(± 13.2) in seronegative polyarthritis and 17.6 (± 2.44) in
ERA+JPsA. The log rank test did not show a significant dif-
ference between the JIA categories survival curves (p =
0.1). In our cohort about one-third of cases obtained a
remission episode in 4 decades of observation. Finally, if
a remission was achieved, the mean duration before a
relapse was about 20 months.
from 15th Paediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008
Published: 15 September 2008
Pediatric Rheumatology 2008, 6(Suppl 1):P105 doi:10.1186/1546-0096-6-S1-P105
<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.ped-rheum.com/content/6/S1/P105
© 2008 Fantini et al; licensee BioMed Central Ltd. 
